Skip to Content

Uday R. Popat, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

 

Dr. Uday Popat graduated from the Lokmanya Tilak Municipal Medical College in Bombay, India. He completed the residency and fellowship programs at institutions in the United Kingdom, India and the United States including Baylor College of Medicine and the University of Texas M. D. Anderson Cancer Center. He is currently an Associate Professor of Medicine in the department of Stem Cell Transplantation and Cellular Therapy at U.T. M. D. Anderson Cancer Center.

Research Interests

Myelofibrosis: Reduced intensity allogeneic transplantation(SCT) for myelofibrosis: This is a novel study, first protocol in this disease at MDACC and the largest single center study, which is still accruing patients. Our preliminary results are encouraging. If these hold over a period of time, this should become standard of care and establish allogeneic transplant as a viable, curative therapy. In a separate study we showed that long term remission was possible in patients with AML post MF after SCT. This finding has not been previously reported.

Multiple Sclerosis:  My previous study and current ongoing study at MDACC will go some way in establishing a role for autologous transplantation in this disease. Our study on allogeneic transplantation for patients with ALS was novel and although negative for clinical endpoints did show significant trafficking of donor hematopoietic stem cells to diseased areas in central nervous system.

Imapct of comorbidities on SCT: To identify patients most suitable for allo transplant and to identify the most suitable transplant strategy for patients with comorbidities.

Risk factors predicting stem cell mobilization failure.

Education & Training

Degree-Granting Education

2003 Royal College of Pathologists, London, United Kingdom, FRCPath, Hematology
1995 Royal College of Pathologists, London, United Kingdom, MRCPath, Hematology
1991 Royal College of Physicians, London, United Kingdom, MRCP, Internal Medicine
1988 University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bomabay, India, MD, Internal Medicine
1984 University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, India, MB, BS, Med School

Board Certifications

1/2001 American Board of Internal Medicine, Medical Oncology
1/2001 American Board of Internal Medicine, Hematology
1/2000 American Board of Internal Medicine, Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Associate Program Director, Stem Cell Transplant Fellowship, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2008-present

Institutional Committee Activities

Member, Infection Control Committee, UT M. D. Anderson Cancer Center, 2008-present
Member, Infection Control Core Group, UT M. D. Anderson Cancer Center, 2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(6):718-23, 6/2009. e-Pub 4/8/2009. PMID: 19450756.
2. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 6/2009. e-Pub 3/2009. PMID: 19384931.
3. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326-34, 10/2008. PMID: 18936424.
4. Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37(6):547-52, 3/2006.
5. Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9):3486-3488, 2006.
6. Lamba R , Carrum G , Myers GD, Bollard CM , Krance RA , Heslop HE , Brenner MK , Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplantation 36(9):797-802, 11/2005.
7. Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant 35(12):1127-32, 6/2005. PMID: 15834432.
8. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105(10):4115-9, 5/2005. PMID: 15671439.
9. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 105(5):1898-904, 3/2005.
10. Rice L, Popat U. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. American Journal of Hematology 78(1):71-73, 2005.
11. Popat U, Frost A, Liu E, May R, Bag R, Reddy V, Prchal JT. New onset of myelofibrosis in association with pulmonary arterial hypertension. Annals of Internal Medicine 143(6):466-467, 2005.
12. Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 126(5):637-49, 9/2004.
13. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 127(Pt5):996-1008, 5/2004. PMID: 14985264.
14. Ganguly S, Carrum G, Nizzi F, Heslop HE, Popat U. Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. Am J Hematol 75(1):48-51, 1/2004. PMID: 14695632.
15. Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treatment Review 29(1):3-10, 2003. PMID: 12633575.
16. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 16:63-9, 1998. PMID: 9440724.

Grant & Contract Support

Title: High dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 10/1/2007 - 2/28/2013
 
Title: Blood and Marrow Transplant Clinical Trials Research Network (BMT CTN)
Funding Source: NIH/NHLBI
Role: Collaborator
Principal Investigator: Sergio Giralt
Duration: 10/1/2006 - 9/30/2011

Last updated: 9/23/2009